-
A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFRmutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
This study is to see if a new medicine called AK112 can help patients with advanced non-squamous non-small cell lung cancer (NSCLC) that didn't ...